Rigel D F, Olson R W, Lappe R W
Research Department, CIBA-GEIGY Corp., Summit, N.J. 07901.
Circ Res. 1993 May;72(5):1091-102. doi: 10.1161/01.res.72.5.1091.
Recombinant desulfatohirudin (HI), a potent and specific thrombin inhibitor, was compared with heparin (HE) as an adjunct to streptokinase thrombolysis. In pentobarbital-anesthetized dogs, an occlusive thrombus (whole blood+thrombin) was introduced into the left anterior descending coronary artery (LAD) with superimposed endothelial damage and distal high-grade stenosis. Intravenous infusion of saline (vehicle), HI (0.3 mg/kg followed by 0.3 mg/kg per hour, 1 mg/kg followed by 1 mg/kg per hour, or 2 mg/kg followed by 2 mg/kg per hour), or HE (60 units/kg followed by 40 units/kg per hour or 100 units/kg followed by 60 units/kg per hour) was initiated 15 minutes before streptokinase (750,000 units for 60 minutes) administration. Vessel patency was monitored for 180 minutes after streptokinase administration with a volume flow probe on the proximal LAD. In dogs treated with no adjunctive agent (saline control), none of the vessels were recanalized with streptokinase. Both HI and HE promoted reperfusion, inhibited reocclusion, and reduced the residual thrombus mass in a dose-dependent fashion. However, at comparable levels of therapeutic anticoagulation (activated partial thromboplastin time [APTT] = 1.5-2.0 times baseline) HI exhibited a higher incidence of reperfusion (eight of eight dogs [100%] versus one of eight dogs [12%]), a shorter time to reperfusion (33 +/- 6 versus 59 minutes), a longer duration of initial reperfusion (106 +/- 21 versus 10 minutes), and a smaller residual thrombus mass than did HE. Likewise, the slope of the relation between the APTT prolongation and the total reperfusion time ("anticoagulation/antithrombosis profile") was almost five times higher for the combined HI data than for the HE data. Our results indicate that HI is more effective than HE in enhancing and sustaining coronary recanalization with streptokinase at a HI dose that modestly prolongs coagulation time and does not alter bleeding times.
重组去硫酸水蛭素(HI)是一种强效且特异性的凝血酶抑制剂,将其作为链激酶溶栓的辅助药物与肝素(HE)进行了比较。在戊巴比妥麻醉的犬中,将闭塞性血栓(全血+凝血酶)注入左前降支冠状动脉(LAD),同时造成内皮损伤和远端高度狭窄。在链激酶(750,000单位,持续60分钟)给药前15分钟开始静脉输注生理盐水(溶媒)、HI(0.3毫克/千克,随后每小时0.3毫克/千克;1毫克/千克,随后每小时1毫克/千克;或2毫克/千克,随后每小时2毫克/千克)或HE(60单位/千克,随后每小时40单位/千克;或100单位/千克,随后每小时60单位/千克)。在链激酶给药后,用近端LAD上的体积流量探头监测血管通畅情况180分钟。在未使用辅助药物治疗的犬(生理盐水对照)中,链激酶未能使任何血管再通。HI和HE均以剂量依赖的方式促进再灌注、抑制再闭塞并减少残余血栓量。然而,在相当的治疗性抗凝水平(活化部分凝血活酶时间[APTT]=基线的1.5 - 2.0倍)下,HI的再灌注发生率更高(八只犬中的八只[100%]对比八只犬中的一只[12%]),再灌注时间更短(33±6对比59分钟),初始再灌注持续时间更长(106±21对比10分钟),且残余血栓量比HE更小。同样,联合HI数据的APTT延长与总再灌注时间之间关系的斜率(“抗凝/抗血栓图谱”)几乎是HE数据的五倍。我们的结果表明,在适度延长凝血时间且不改变出血时间的HI剂量下,HI在增强和维持链激酶介导的冠状动脉再通方面比HE更有效。